V.THRM | 4 hours ago
Toronto, Ontario–(Newsfile Corp. – February 24, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the Company has been recognized in the 2022 TSX Venture 50 for top-performing stocks, and ranked in the top three (3) for the Life Sciences sector.
The 2022 TSX Venture 50 winners were selected based on year-over-year performance across three (3) equally weighted criteria: market capitalization growth, share price appreciation and trading volume for the year ended December 31, 2021. Therma Bright joins 49 other top performing TSX Venture companies across five (5) sectors in this honor. Learn more at TSX.com/Venture50.
“Therma Bright is honored to be placed in the TSX Venture 50 for top performing stocks and ranked third in the Life Sciences category,” shared Rob Fia, CEO of Therma Bright. “With a solid 2022 outlook on our growing progressive diagnostic and medical device business, which includes our smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test that is moving through the U.S. Food & Drug Administration’s Emergency Use Authorization (EUA) process, our reseller partnership with DME Authority for our Venowave, Deep Vein Thrombosis Device, and our recent U.S. Patent for our TherOZap™ and InterceptCS™ technology, we’re poised to not only transform innovation into wellness, but also transform these wellness solutions into profits.”
Therma Bright is not making any express or implied claims that its AcuVid™ COVID-19 Rapid Antigen Saliva Test has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.